New hope for rare genetic cancers? drug targets POLE/POLD1 mutations

NCT ID NCT03810339

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called toripalimab, which helps the immune system fight cancer, in people with advanced solid tumors that have specific genetic changes (POLE or POLD1 mutations) and have not responded to standard treatments. The trial aims to see if the drug can shrink tumors or slow disease progression. About 35 adults aged 18-75 will receive the drug every 3 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab (a PD-1 antibody)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have specific genetic mutations (POLE/POLD1) and haven't responded to standard therapy.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 35 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects like immune-related inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER SOLID TUMOR

Contacts and locations

Locations

Cancer center of Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 510060, China
The Affiliated Hospital of Guizhou Medical University
RECRUITING

Guiyang, Guizhou, China
The Second Affiliated Hospital of Dalian Medical University
RECRUITING

Dalian, Liaoning, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.